Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:AEX NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEXAEX GoldC$0.62-1.6%C$0.62C$0.44▼C$0.82C$109.80MN/A28,496 shs8,500 shsPHARPharming Group$13.72-6.6%$12.09$7.31▼$17.08$939.62M0.056,684 shs13,159 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEXAEX Gold0.00%0.00%0.00%0.00%0.00%PHARPharming Group0.00%-2.97%+26.01%+29.95%+95.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEXAEX GoldC$0.62-1.6%C$0.62C$0.44▼C$0.82C$109.80MN/A28,496 shs8,500 shsPHARPharming Group$13.72-6.6%$12.09$7.31▼$17.08$939.62M0.056,684 shs13,159 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEXAEX Gold0.00%0.00%0.00%0.00%0.00%PHARPharming Group0.00%-2.97%+26.01%+29.95%+95.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEXAEX Gold 0.00N/AN/AN/APHARPharming Group 3.00Buy$30.00118.74% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEXAEX GoldN/AN/AC$0.13 per share4.59C$0.21 per shareN/APHARPharming Group$297.20M3.16$0.07 per share198.04$3.25 per share4.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEXAEX GoldN/A-C$0.14N/A∞N/AN/AN/AN/AN/APHARPharming Group-$11.84M-$0.13N/A457.17N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)Latest CHAR, FOG, PHAR, and AEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEXAEX GoldN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEXAEX Gold2.0919.9019.77PHARPharming Group0.382.792.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEXAEX GoldN/APHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipAEXAEX GoldN/APHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEXAEX GoldN/A177.10 millionN/ANot OptionablePHARPharming Group28068.51 million67.10 millionNot OptionableCHAR, FOG, PHAR, and AEX HeadlinesRecent News About These CompaniesHead to Head Survey: Pharming Group (NASDAQ:PHAR) versus Mersana Therapeutics (NASDAQ:MRSN)September 15 at 4:05 AM | americanbankingnews.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Increase in Short InterestSeptember 14 at 7:59 AM | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Up - Still a Buy?September 13 at 10:57 AM | marketbeat.comPharming Group N.V.: Pharming Group promoted to the Euronext AMX indexSeptember 10, 2025 | finanznachrichten.dePharming Group promoted to the Euronext AMX® indexSeptember 10, 2025 | markets.businessinsider.comPharming Group N.V. (PHAR) Presents at H.C. Wainwright 27th Annual Global Investment Conference - SlideshowSeptember 8, 2025 | seekingalpha.comPharming Group (NASDAQ:PHAR) Shares Up 5% - Should You Buy?September 5, 2025 | marketbeat.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Down 73.1% in AugustSeptember 5, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What HappenedSeptember 4, 2025 | marketbeat.comPharming Group to present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | finance.yahoo.comPharming Group names new finance headSeptember 2, 2025 | msn.comPharming Group appoints Kenneth Lynard as Chief Financial OfficerSeptember 2, 2025 | markets.businessinsider.comWall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High?August 22, 2025 | zacks.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short InterestAugust 17, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Trading 1.2% Higher - Still a Buy?August 16, 2025 | marketbeat.comPharming Group NV (PHARMA.XD) - Yahoo FinanceAugust 10, 2025 | finance.yahoo.comWall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a BetAugust 6, 2025 | zacks.comPharming Group N.V. Reports Strong Q2 EarningsAugust 4, 2025 | theglobeandmail.comPharming Group to participate in August investor conferenceAugust 4, 2025 | uk.finance.yahoo.comPharming Group Second Quarter 2025 Earnings: EPS: US$0.007 (vs US$0.002 loss in 2Q 2024)August 2, 2025 | finance.yahoo.comPharming Group N.V. (PHAR) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAmazon’s Chart Just Flashed a Pennant Pattern—Here’s What to DoBy Sam Quirke | August 27, 2025Hyperscaler Spending Could Supercharge Super Micro Computer StockBy Gabriel Osorio-Mazilli | August 19, 20253 Biotech Catalysts Present Major OpportunityBy Nathan Reiff | August 25, 2025Which States Have the Highest Interest Rates on Family Loans? [2025 Survey]By MarketBeat Staff | August 25, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025CHAR, FOG, PHAR, and AEX Company DescriptionsAEX Gold CVE:AEXC$0.62 -0.01 (-1.59%) As of 07/11/2022AEX Gold Inc. engages in the acquisition, exploration, and development of mineral properties in Greenland. It holds interests in licenses covering an area of 7,615.85 square kilometers located in South Greenland. The company was formerly known as Alopex Gold Inc. and changed its name to AEX Gold Inc. in June 2018. AEX Gold Inc. was incorporated in 2017 and is headquartered in Toronto, Canada.Pharming Group NASDAQ:PHAR$13.72 -0.97 (-6.57%) Closing price 03:57 PM EasternExtended Trading$13.72 0.00 (0.00%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
